Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data

  • Published on 06/07/2024
  •  Reading time: 4 min.

Christina Qian 1 , Alexa C. Klimchak 2 , Katherine L. Gooch 2  

1 Broadstreet Health Economics and Outcomes Research, 201-343 Railway Street, Vancouver, BC, V6A 1A4, Canada
2 Sarepta Therapeutics, Inc, 215 First Street, Cambridge, MA, 02142, USA


Introduction Duchenne muscular dystrophy (DMD) is a rare, severe progressive neuromuscular disease. Health insurance claims allow characterization of population-level real-world outcomes, based on observed healthcare resource use. An analysis of data specific to those with Medicaid insurance is presently unavailable. The objective was to describe the real-world clinical course of DMD based on claims data from Medicaid-insured individuals in the USA.


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Rare Diseases

Receive our newsletter to stay up to date with the latest news in Rare Diseases